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ABSTRACT: Background: Corneal confocal micros-
copy (CCM) is a noninvasive, reproducible ophthalmic
technique to quantify corneal small nerve fiber degenera-
tion. CCM demonstrates small nerve fiber damage in
Parkinson’s disease (PD), but its role as a longitudinal
biomarker of PD progression has not been explored.
Objective: The aim of this study was to assess corneal
nerve morphology using CCM in relation to disease pro-
gression in PD.
Methods: Sixty-four participants with PD were assessed
at baseline and at 12-month follow-up. Participants
underwent CCM with automated corneal nerve quantifi-
cation and assessment of Movement Disorder Society
Unified Parkinson’s Disease Rating Scale, Hoehn and
Yahr stage, and Montreal Cognitive Assessment.
Results: Corneal nerve fiber density (CNFD), corneal nerve
branch density, corneal nerve fiber length, corneal total
branch density, and corneal nerve fiber area were signifi-
cantly lower in participants with PD compared with healthy
control subjects. Worsening of Movement Disorder Society
Unified Parkinson’s Disease Rating Scale part III score over
12 months was significantly greater in participants with a
CNFD in the lowest compared with the highest quartile at
baseline (mean difference: 6.0; 95%CI: 1.0–10.9; P = 0.019).
There were no significant changes in CNFD, corneal nerve
branch density, corneal nerve fiber length, corneal total
branch density, corneal nerve fiber area, or corneal nerve
fiber width between baseline and 12-month follow-up.
Conclusions: CCM identifies neurodegeneration in patients
with PD, especially those who show the greatest progression
in neurological disability. CCM may be a useful tool to help
enrich clinical trials with those likely to exhibit more rapid pro-
gression and reduce required sample size and cost of studies.
©2021TheAuthors.Movement DisorderspublishedbyWiley
Periodicals LLC on behalf of International Parkinson and
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Parkinson’s disease (PD) is a heterogenous clinical
syndrome in relation to both movement disorder and
associated nonmotor manifestations. Indeed, nonmotor
features, such as autonomic dysfunction,1 sleep dis-
orders,2 and peripheral neuropathy,3 have prognostic
value and may indicate distinct subtypes of PD.4
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
*Correspondence to: Sze Hway Lim, Department of Neurology, Salford
Royal NHS Foundation Trust, Manchester Academic Health Sciences
Centre, University of Manchester, Manchester, UK;
E-mail: szehway.lim@postgrad.manchester.ac.uk
Relevant conflicts of interest/Financial disclosures: S.H.L., M.F., A.
K., Z.R.M., and I.N.P. have no disclosures. Rayaz A. Malik has received
grant funding from the Michael J. Fox Foundation, NIH, and Qatar Foun-
dation; speaker fees from Novo Nordisk, Pfizer, and Merck; payment for
advisory boards from Merck and Pfizer. C.K. has received grant funding
from Parkinson’s UK and Michael J. Fox Foundation; speaker fees from
Britannia and Bial Pharma; support to attend international meetings from
AbbVie and Merz Pharma; payment for advisory boards from Britannia
and AbbVie. M.S. has received grant funding from Parkinson’s UK and
Michael J. Fox Foundation; meeting honoraria from UCB, as well as
conference expenses from Bial, AbbVie, and Medtronic.
Full financial disclosures and author roles may be found in the online
version of this article.
Received: 15 December 2020; Revised: 11 March 2021; Accepted: 12
March 2021
Published online 7 April 2021 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.28602
Movement Disorders, Vol. 36, No. 8, 2021 1927
Peripheral nerves are a target for α-synuclein
deposition,5-7 and peripheral neuropathy3 and auto-
nomic dysfunction1 have been associated with more
severe disease phenotypes. Subtyping PD may enable a
better understanding of disease mechanisms and predic-
tion of disease progression.
Skin biopsies in people with PD demonstrate α-synuclein
deposition and small fiber neurodegeneration.7-9 Higher
α-synuclein ratios have been correlatedwithmore advanced
disease in PD,9 and cutaneous small fiber degeneration has
been correlatedwithmotor severity.8
Corneal confocal microscopy (CCM) is a novel non-
invasive ophthalmic method that enables in vivo quan-
tification of small nerve fiber damage. It was initially
developed to overcome the limitations of light micros-
copy, which can only study corneal nerve architecture
in vitro and produces poor-resolution images.10 The
cornea has the densest small fiber innervation in the
body and has a central corneal nerve density of approx-
imately 7000 nociceptors per square millimeter,
resulting in the cornea being 300 to 600 times more
sensitive than skin.11 CCM has been used to detect
small fiber degeneration in a range of peripheral neu-
ropathies, including diabetic neuropathy,12 idiopathic
small fiber neuropathy,13 chronic inflammatory demye-
linating polyneuropathy,14 and Charcot–Marie–Tooth
disease.15 The key parameters to quantify corneal nerve
morphology are corneal nerve fiber density (CNFD); a
measure of the number of main nerves, corneal nerve
branch density (CNBD); a measure of the number of
branch points and corneal nerve fiber length (CNFL);
and a measure of the total length of main nerves and bra-
nches (see Fig. 2). More recently, fully automated analy-
sis has enabled the quantification of corneal nerve fiber
area (CNFA), corneal nerve fiber width (CNFW), and
corneal total branch density (CTBD).16 CNFD has been
shown to have a better sensitivity and specificity compared
with intraepidermal nerve fiber density from skin biopsies
in the diagnosis of diabetic polyneuropathy.17,18 CCM can
also identify early nerve regeneration evidenced by an
increase in CNFD and CNFL after simultaneous kidney
and pancreas transplantation in patients with type 1 diabe-
tes19 and CNFD, CNBD, and CNFL after bariatric surgery
in patients with obesity.20 CCM has undergone multiple
validation studies and has been shown to be a reliable and
highly reproducible corneal nerve imaging technique.21,22
Several cross-sectional studies using CCM have dem-
onstrated corneal nerve fiber degeneration in participants
with PD compared with control subjects.23-25 Our initial
pilot study of CCM in 26 participants with PD demon-
strated a decrease in CNFD and an increase in CNBD
and CNFL compared with control subjects, indicative of
proximal nerve degeneration with more distal nerve
regeneration.23 Several skin biopsy studies have reported
cutaneous denervation in PD compensated by nerve
regeneration (suggested by the presence of increased
nerve branching), which declines over time.26,27 Our
more recent study of 98 participants with PD demon-
strated a reduction in all CCM parameters compared
with control subjects.28 Nerve regeneration may result in
an increase in branches and total length of nerves; thus,
CNBD and CNFL may vary according to the stage of
disease. All PD studies using CCM to date have been
cross sectional, which does not allow an assessment of
the utility of quantifying CCM parameters to predict dis-
ease progression. In this study, we have assessed corneal
nerve morphology at baseline and over 12 months in
relation to change in disease severity in patients with PD.
Subjects and Methods
National Research Ethics Service (NRES) Committee/
North West approved the study (Reference
no. 17/NW/0144). Written informed consent was
obtained from each participant. This research adhered
to the tenets of the Declaration of Helsinki for clinical
research involving human subjects.
Subjects
Patients with PD who fulfilled Queen Square Brain bank
criteria29 were recruited from clinics across Greater Man-
chester and via Fox Trial Finder and Parkinson’s UK
websites between September 2017 and September 2018.
Eighty-four participants were screened based on their clini-
cal history and blood tests (full blood count, urea and elec-
trolytes, glycated hemoglobin, immunofluorescence anti-
nuclear antibodies, B12, folate, immunoglobulins, serum
electrophoresis, and thyroid function tests). Exclusion
criteria were concurrent diagnosis of diabetes, active malig-
nancy, hepatic disease, any known cause of neuropathy,
chronic corneal pathologies, history of refractive surgery,
and any systemic disease known to affect the cornea, such
as Fabry’s disease, chronic kidney disease, and Sjogren’s
disease. Seventy-five participants with PD were enrolled
into the study, and 64 were followed up after 12 months
(Supporting Information Fig. S1).
Twenty-five healthy volunteers were recruited as con-
trol subjects and compared with the baseline CCM
parameters of the 64 participants with PD.
Medical History and Neurological Assessment
Participants’ age, sex, medical history, and medica-
tions, including dopaminergic therapy, were docu-
mented. Levodopa-equivalent daily dose was calculated
according to validated conversion tables.30-32 Disease
duration was calculated from the date of diagnosis to the
date of assessment. All participants underwent a neuro-
logical examination to exclude participants with clini-
cally manifest peripheral neuropathy. All parts of the
Movement Disorder Society Unified Parkinson’s Rating
Scale (MDS UPDRS)33 were performed on participants
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in the ON state, the Hoehn Yahr scale was used to assess
disease stage, and cognitive function was assessed using
the Montreal Cognitive Assessment (MoCA)34 scale.
Ophthalmic Assessment
All ophthalmic assessments were performed by trained
optometrists. Both eyes were first assessed with a slit-
lamp biomicroscope (Slit Lamp BD 900; Haag-Streit,
Koeniz, Switzerland) to exclude anterior eye pathology.
Laser scanning CCM (Rostock Cornea Module/Heidel-
berg Retina Tomograph lll; Heidelberg Engineering
GmbH, Heidelberg, Germany) was performed at base-
line and after 12 months of follow-up. CCM was per-
formed with patients in the ON state to minimize
interference from motor symptoms. A drop of 0.4%
benoxinate hydrochloride (Oxybuprocaine Hydro 0.4%;
Bausch & Lomb, Surrey, UK) was used to anesthetize
each eye. Viscotears (Carbomer 980, 0.2%; Novartis,
London, UK) was also applied to the participants’ eyes
to reduce any discomfort. Head/chin frames were used
to stabilize the position of the participant’s head. The
participants were asked to fixate on an outer fixation
target with the contralateral eye and a charge-coupled
device was used to identify the exact location of the cam-
era on the corneal surface during the examination.
The full thickness of the central cornea was scanned
using the section mode, and 2D images measuring
384 × 384 μm with optical resolution of 10 μm/pixel
were obtained. Multiple images of the subbasal plexus
were taken and stored in a database. The total time taken
to acquire CCM images for each patient was 10 min.
Six high-quality (three per eye) images of the subbasal
nerve plexus were selected for each patient, following an
established protocol to eliminate any variability in image
selection.21 Automated CCMetrics software, version 2.0
(University of Manchester, Manchester, UK) was used to
quantify the nerve fibers. This fully automated analysis
ensures blinded quantification of six corneal nerve param-
eters: CNFD, the number of main nerves per frame (num-
ber [no.]/mm2); CNBD, the number of branches arising
from major nerves (no./mm2); CNFL, the total length of
all nerve fibers and branches (mm/mm2); CTBD, the total
number of branches per frame (no./mm2); CNFA, the
total area of nerve fibers per frame (μm2/mm2); and
CNFW, the average axial diameter of nerve fibers per
frame (μm). A mean was derived for each parameter.
Statistical Analysis
IBM SPSS version 25 was used to analyze the results.
Normality of distribution was assessed by the Shapiro-
Wilk test. Means of continuous data for participants
with PD and control subjects at baseline were com-
pared using an independent t test for normally distrib-
uted data and Mann-Whitney U test for nonparametric
data. Cohen’s d was calculated to measure effect size:
d = 0.2 (small), d = 0.5 (medium), d = 0.8 (large).35 χ2
test was used to compare categorical data. Paired sam-
ples t test was used to compare means of normally dis-
tributed data at baseline and 12-month follow-up. The
McNemar-Bowker test was used to compare propor-
tions of paired categorical outcomes.
To compare rate of disease progression in participants
with the most and least corneal nerve damage at baseline,
we divided participants into four quartiles based on their
baseline CCM parameter values. An independent t-test
was used to compare the means of change in MDS
TABLE 1. Clinical characteristics and corneal confocal microscopy parameters of participants with PD at baseline and
12-month follow-up
Baseline 12-Month Follow-up P
Clinical scores/LEDD
MDS UPDRS II 10.5  6.7 11.1  6.8 0.203
MDS UPDRS III 27.4  10.3 31.5  12.3 <0.001*
Full MDS UPDRS 52.0  19.4 58.1  20.0 <0.001*
Hoehn & Yahr stage I:9, II:45, III: 10
2 (2, 2)
I:7, II:49, III:7, IV:1
2 (2, 2)
0.593
MoCA 26.5  2.8 26.1  3.4 0.297
LEDD 483.5  260.7 578.5  312.8 <0.001*
CCM parameters
CNFD (no./mm2) 24.47  7.28 24.75  7.80 0.707
CNBD (no./mm2) 25.24  13.32 27.12  15.86 0.191
CNFL (mm/mm2) 14.06  3.48 14.17  3.63 0.703
CTBD (no./mm2) 36.22  18.53 38.95  20.16 0.170
CNFA (μm2/mm2) 5234  1419 5200  1611 0.812
CNFW (μm) 20.67  0.98 20.5  1.00 0.273
Data are shown as mean  SD apart from Hoehn & Yahr score (median with interquartile range).
LEDD, levodopa-equivalent daily dose; MDS UPDRS II, Movement Disorder Society Unified Parkinson’s Disease Rating Scale part II; CCM, corneal confocal
microscopy; MoCA, Montreal Cognitive Assessment; CNFD, corneal nerve fiber density; CNBD, corneal nerve branch density; CNFL, corneal nerve fiber length;
CTBD, corneal total branch density; CNFA, corneal nerve fiber area; CNFW, corneal nerve fiber width.
*P < 0.05 was considered statistically significant.
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UPDRS part III (MDS UPDRS III) scores after 12 months
between participants in quartiles 1 and 4.
Linear regression was used to measure the variation in
change in MDS UPDRS III scores after 12 months in partici-
pants with the lowest number of nerves (CNFD quartile 1)
compared with the highest number of nerves (CNFD quartile
4) after adjusting for the effects of age, sex, and disease dura-
tion. The first linear regression model consisted of “CNFD
quartile 1 versus CNFDquartile 4” as the independent variable.
The second linear regression model studied the effects of
“CNFD quartile 1 versus CNFD quartile 4” on change in
MDS UPDRS III after 12 months, after adjusting for the effects
of age, disease duration, and sex by entering all four factors as
independent variables. Tests for linearity, homoscedasticity,
multicollinearity, influential data points, and normality showed
that the assumptions of the regression analysis were met.
Spearman’s correlation was used to assess for correla-
tion between change in levodopa-equivalent daily dose,
change in CCM parameters, change in MDS UPDRS
scores, and change in MoCA over 12 months.
Data were reported as mean ± SD, and P < 0.05 was
considered statistically significant. The study was an
FIG. 1. Corneal confocal microscopy parameters in participants with Parkinson’s disease (PD) compared with control subjects. Mean ± 95% CI of cor-
neal nerve fiber density (CNFD), corneal nerve branch density (CNBD), corneal nerve fiber length (CNFL), corneal nerve total branch density (CTBD),
corneal nerve fiber area (CNFA), and corneal nerve fiber width (CNFW) in patients with PD compared with controls with significance levels and Cohen’s
d effect size. no, number. [Color figure can be viewed at wileyonlinelibrary.com]
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exploratory study, and therefore corrections for multi-
ple comparisons were not performed.
Results
Demographics and Clinical Characteristics
of Participants
Sixty-four participants with PD (16 female, 48 male),
with a mean age of 64.1 ± 7.8 years, and 25 control
participants (11 female, 14 male), with a mean age of
63.1 ± 6.8 years, were recruited to the study. There was
no significant difference in age (P = 0.56) or sex
(P = 0.08) between the PD cohort and the control
cohort. The participants with PD were followed up
after a mean duration of 12.0 ± 1.0 month. The mean
duration of PD was 56.9 ± 42.6 months at visit 1 (base-
line). Clinical characteristics at visits 1 and 2 (12-month
follow-up) are summarized in Table 1.
Corneal Nerve Morphology in
Participants with PD at Baseline and in
Control Subjects
CNFD, CNBD, CNFL, CTBD, and CNFA were sig-
nificantly lower in participants with PD at baseline
compared with control subjects (CNFD mean differ-
ence: 4.55 no./mm2, 95% CI: 1.31–7.79, d = 0.7,
P = 0.006; CNBD mean difference: 8.18 no./mm2, 95%
CI: 2.31–14.05, d = 0.7, P = 0.003; CNFL mean differ-
ence: 2.53 mm/mm2, 95% CI: 0.94–4.11, d = 0.8,
P = 0.002; CTBD mean difference: 11.19 no./mm2,
95% CI: 2.92–19.45, d = 0.7, P = 0.003; and CNFA
mean difference: 773.9 μm2/mm2, 95% CI: 97.0–
1450.8, d = 0.5, P = 0.026). CNFW did not differ sig-
nificantly between participants with PD and control
subjects (CNFW mean difference: −0.257 μm, 95% CI:
0.23–0.20, d = 0.3, P = 0.158) (Figs 1 and 2).
Corneal Nerve Morphology in Participants With
PD at Baseline and 12-Month Follow-up
Across the whole PD cohort, there were no significant
changes in CCM parameters between baseline and
follow-up at 12 months (Table 1).
FIG. 2. Corneal confocal microscopy images. Corneal confocal microscopy image of a healthy control (A), an age-matched participant with Parkinson’s
disease (PD) (B), and the participant with PD after 12 months (C). Corneal nerve fiber density is the total number of main nerves (indicated by red
arrows) per square millimeter (no./mm2), corneal nerve branch density is the total number of junctions between branches (indicated by yellow arrows)
and main nerves (red arrows) per square millimeter (no./mm2), corneal nerve fiber length is the total length of main nerves and nerve branches per
square millimeter (mm/mm2). [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2. Change in MDS UPDRS III over 12 months
between participants corneal nerve parameters in quartile 1
(most severe corneal nerve degeneration) compared with






III After 12 Months P
CNFD quartile 1 17 6.9  8.0 0.019*
CNFD quartile 4 18 0.9  6.3
CNBD quartile 1 16 5.4  7.8 0.406
CNBD quartile 4 17 3.1  7.5
CNFL quartile 1 16 5.6  8.1 0.367
CNFL quartile 4 16 3.0  7.7
CTBD quartile 1 16 3.5  9.7 0.658
CTBD quartile 4 16 2.3  5.7
CNFA quartile 1 17 4.9  9.3 0.796
CNFA quartile 4 16 4.1  8.6
CNFW quartile 1 16 5.9  7.7 0.228
CNFW quartile 4 16 1.9  10.5
Data are reported as mean  SD.
MDS UPDRS III, Movement Disorder Society Unified Parkinson’s Disease
Rating Scale part III; CNFD, corneal nerve fiber density; CNBD, corneal nerve
branch density; CNFL, corneal nerve fiber length; CTBD, corneal total branch
density; CNFA, corneal nerve fiber area; CNFW, corneal nerve fiber width.
*P < 0.05 was considered statistically significant.
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Disease Progression Between Patients Based
on Severity of Baseline Impairment of Corneal
Nerve Parameters
The change in MDS UPDRS III over 12 months was
significantly different between patients in quartile
1 (most severe corneal nerve degeneration) compared
with quartile 4 (least severe corneal nerve degeneration)
for CNFD and did not differ for CNFL, CNBD, CTBD,
CNFW, and CNFA (Table 2).
Regression Analysis
Compared with patients in quartile 4, those in quar-
tile 1 of CNFD had a significantly greater increase in
MDS UPDRS III after 12 months (mean differen-
ce = 5.99, P = 0.019). This difference remained signifi-
cant even after adjusting for age, sex, and duration of
the disease of the participants (adjusted mean differen-
ce = 5.55, P = 0.036) (Table 3).
Correlations Between Change in
Levodopa-Equivalent Daily Dosage, MDS
UPDRS Scores, and Change in CCM
Parameters
There were no correlations between change in levodopa-
equivalent daily dose and change in CNFD (Rho = −0.143,
P = 0.260), MDS UPDRS II (Rho = −0.155, P = 0.221),
MDS UPDRS III (Rho = −0.047, P = 0.715), full MDS
UPDRS (Rho = −0.168, P = 0.185), and MoCA (Rho =
−0.047,P = 0.715) over 12 months.
Discussion
This study confirms previous findings by our group23,28
and others24,25 of corneal nerve damage in patients with PD
compared with healthy control subjects. Although there
was no significant decline in corneal nerve parameters over
12 months, intriguingly, participants with a baseline CNFD
in the lowest quartile (most severe corneal nerve degenera-
tion) compared with the highest quartile (least severe cor-
neal nerve degeneration) showed the most rapid clinical
deterioration based on an increase in MDS UPDRS III.
Studies in patients with diabetic neuropathy have shown
that it may take 2 to 4 years for a significant reduction in
corneal nerve parameters.36,37 A recent study in 590
patients with diabetes followed over 5 years demon-
strated more rapid corneal nerve loss in a subgroup of par-
ticipants who showedmore rapid worsening of neuropathy
andwere referred to as progressors.38
In this study, there was overlap in CCM parameters
between the control cohort and the PD cohort,
suggesting that there are subgroups of patients with PD
with different degrees of corneal denervation. Indeed,
we show that the severity of small nerve fiber degenera-
tion at baseline may confer a poorer prognostic out-
come in relation to greater worsening of motor
disability over 12 months after adjusting for age, sex,
and disease duration. The six-point increase in MDS
UPDRS III after 12 months between patients with the
least and most corneal nerves at baseline exceeds the
margin of 4.6, which is considered to be a clinically
important worsening of the MDS UPDRS III score.39
Extranigral involvement and nonmotor features have
been increasingly used to subtype PD and assess rates
of disease progression. A recent cluster analysis study
identified that three nonmotor features (rapid eye move-
ment sleep behavior disorder, mild cognitive impair-
ment, and orthostatic hypotension) at baseline predict
the most rapidly progressive subtype termed the “dif-
fuse malignant subtype.”40 The authors have suggested
that the diffuse malignant subtype may represent diffuse
neurodegenerative pathology because the features
involve the simultaneous dysfunction of different ana-
tomical regions.41 Other studies have also demon-
strated that autonomic dysfunction is associated with a
more severe PD phenotype with a greater risk for falls,
wheelchair dependence, and cognitive impairment.42
Neuropathy is associated with worse motor and cogni-
tive scores and nonmotor disability.3 Interestingly, a
recent study has shown that the reduction in the gan-
glion cell-inner plexiform layer and peripapillary retinal
nerve fiber layer thickness over 3 years was related to
cognitive decline, but not motor deterioration, in
patients with PD.43 In this study, CNFD had prognostic
value for motor deterioration because it is a more stable
measure of proximal nerve degeneration, whereas
CNFL, CNBD, and CTBD are more variable due to
ongoing distal nerve regeneration.8 Indeed, our previ-
ous study showed a decrease in CNFD but an increase
in CNBD and CNFL in PD.15
PD-related peripheral neuropathy may be caused by
the iatrogenic effects of dopaminergic therapies and
intrinsic neurodegeneration. Studies have demonstrated
an association between therapy with levodopa and
large fiber neuropathy,44 but not small fiber neuropa-
thy.45 Many studies have suggested that small fiber neu-
ropathy is an intrinsic part of the disease process in
PD.23,45-47 Nolano and colleagues45 found large and
TABLE 3. Regression analysis













5.55 2.5 0.036* 22.4%
CNFD, corneal nerve fiber density; MDS UPDRS III, Movement Disease Soci-
ety Unified Parkinson’s Disease Rating Scale part III.
*P < 0.05 was considered statistically significant.
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small fiber neuropathy in drug-naive patients and
showed that large, but not small, fiber pathology wors-
ened with levodopa use. Doppler and colleagues46
found no correlation between intraepidermal nerve
fiber density and the cumulative levodopa intake. Our
previous study demonstrated no correlation between
corneal nerve parameters and cumulative levodopa
dose.23 This study also demonstrates no correlation
between change in levodopa daily dose and change in
corneal nerve parameters after 12 months.
Some limitations should be noted. It was not possible
to establish a robust link between peripheral and cen-
tral neurodegeneration because we have not directly
compared CCM parameters with imaging markers of
central dopaminergic neuronal integrity. The number of
patients in the highest and lowest quartiles of CNFD
was relatively small, and the findings require validation
in other PD cohorts. A longer follow-up period will
also be required to fully assess progression of corneal
nerve degeneration in PD.
This study confirms corneal nerve loss in patients
with PD and further suggests that CCM may be a use-
ful marker of neurodegeneration to identify patients
with PD with a more progressive and severe disease
phenotype, termed “fast progressors.” Identification of
slow and fast progressors may allow the identification
and recruitment of patients with PD who are more or
less responsive to disease-modifying therapies48 to
enable the design of shorter, more cost-effective clinical
trials and to eliminate heterogeneity in the PD cohort.
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